Abstract
Enteroviral infection can lead to dilated cardiomyopathy (DCM), which is a major cause of cardiovascular mortality worldwide. However, the pathogenetic mechanisms have not been fully elucidated. Serum response factor (SRF) is a cardiac-enriched transcription regulator controlling the expression of a variety of target genes, including those involved in the contractile apparatus and immediate early response, as well as microRNAs that silence the expression of cardiac regulatory factors. Knockout of SRF in the heart results in downregulation of cardiac contractile gene expression and development of DCM. The goal of this study is to understand the role of SRF in enterovirus-induced cardiac dysfunction and progression to DCM. Here we report that SRF is cleaved following enteroviral infection of mouse heart and cultured cardiomyocytes. This cleavage is accompanied by impaired cardiac function and downregulation of cardiac-specific contractile and regulatory genes. Further investigation by antibody epitope mapping and site-directed mutagenesis demonstrates that SRF cleavage occurs at the region of its transactivation domain through the action of virus-encoded protease 2A. Moreover, we demonstrate that cleavage of SRF dissociates its transactivation domain from DNA-binding domain, resulting in the disruption of SRF-mediated gene transactivation. In addition to loss of functional SRF, finally we report that the N-terminal fragment of SRF cleavage products can also act as a dominant-negative transcription factor, which likely competes with the native SRF for DNA binding. Our results suggest a mechanism by which virus infection impairs heart function and may offer a new therapeutic strategy to ameliorate myocardial damage and progression to DCM.
Similar content being viewed by others
Introduction
Enteroviruses, such as coxsackievirus B3 (CVB3), are among the most prevalent and well-studied etiological agents associated with viral myocarditis, an inflammatory disease of the myocardium 1, 2. Viral myocarditis can lead to reduced cardiac function and the progression to dilated cardiomyopathy (DCM), which is an important cause of cardiovascular mortality worldwide, particularly in children 1, 2. However, the mechanism underlying progression from acute infection to development of a dilated cardiac phenotype is not fully understood.
Enteroviral-encoded proteases have been recognized as important pathogenic factors contributing to the development of DCM. Enterovirus encodes viral proteases 2A and 3C, which cleave multiple host proteins essential for the maintenance of cellular architecture, protein translation, transcription, and cell signaling in addition to the processing of viral polyprotein 1. Transgenic mice with cardiac-restricted expression of protease 2A develop severe cardiac dysfunction and DCM 3. Disruption of the dystrophin-glycoprotein complex through dystrophin cleavage has been proposed as one important mechanism in the progression of DCM 4. However, dystrophin-null mice do not develop equally severe cardiomyopathy 5, 6 as observed in 2A transgenic mice, suggesting that other molecular targets may also exist and contribute to the viral pathogenesis.
Serum response factor (SRF) is a member of the MADS (MCM1, Agamous, Deficiens, and SRF) box superfamily of transcription factors. It binds to serum response element (SRE, also known as CArG box (CC(A/T)6GG)) and is associated with the regulation of a variety of target genes, including immediate early, contractile, and microRNA (miRNA) genes 7, 8, 9. A genome-wide search for SRF targets has identified approximately 1 200 genes, which contain single or more copies of this consensus SRE sequence in their promoter regions (termed CArGome) 10. More than 250 of these genes have been validated 10.
SRF is highly expressed in cardiac muscle and plays a central role in cardiac development and function by regulating genes for cardiac contractile and regulatory proteins as well as silencer miRNAs 11, 12, 13, 14. Recent studies have identified several miRNAs as targets of SRF in the heart, which include miR-486 15, miR-133a 11, 14, and miR-1 16. Expression of these miRNAs controls heart development and function by repressing the expression of cardiac regulatory proteins. In mice, cardiac-specific knockout of SRF gene is embryonic lethal due to defects in cardiogenesis 12, 14, 17. Using the Cre/LoxP system, disruption of SRF gene in adult heart leads to impaired cardiac function, subsequently progressing to DCM 18. Furthermore, we have previously reported that cleavage of SRF by caspase-3 plays an important role in the progression of human heart failure 19.
The objective of the present study is to elucidate a potentially novel molecular mechanism involved in the impaired heart function and development of DCM. Here we demonstrate that SRF is cleaved during CVB3 infection through the action of viral protease 2A. Such cleavage leads to the dissociation of the DNA-binding domain of SRF from its transactivation domain, resulting in the disruption of SRF-mediated gene transactivation and the generation of a dominant-negative transcription factor, which competes with the native SRF for DNA binding. Our results suggest an important mechanism by which CVB3 damages cardiac function and leads to subsequent DCM.
Results
Cardiac function and cardiac gene expression following CVB3 infection
The mouse model of myocarditis has been well characterized and commonly used to study target organ injury during CVB3 infection 20, 21. Two-dimensional echocardiography was performed to assess functional alterations in CVB3-infected mouse hearts. As shown in Figure 1A, virus-infected mice displayed cardiac dysfunction, evidenced by a significant reduction in left ventricular posterior wall (LVPW) thickening and ejection fraction.
Heart failure has been associated with the reduction of a broad range of cardiac-specific genes 22, 23, 24. To determine the cardiac gene expression, we performed microarray analysis of CVB3-infected mouse hearts and real-time RT-PCR examination of CVB3-infected cardiomyocytes. Affymetrix array analyses demonstrated a marked reduction in the expression of several cardiac-specific contractile and regulatory genes (Figure 1B). See Supplementary information, Table S1 for complete list of Affymetrix gene expression data. Quantitative RT-PCR results in Figure 1C also demonstrate downregulation of several cardiac genes, including ANP, β-MHC, GATA-4, MEF-2, and NFAT, in CVB3-infected cardiomyocytes.
Expression levels of SRF following CVB3 infection
As alluded to earlier, SRF is a cardiac-enriched transcription factor, regulating the expression of numerous cardiac-specific genes. To explore whether downregulation of cardiac genes is associated with dysregulation of SRF, we examined the expression levels of SRF during CVB3 infection. Using an antibody against the C-terminus of SRF, we found that CVB3 infection of mouse cardiomyocytes (Figure 2A, top panel) and hearts (Figure 2D) led to marked decreases in the protein expression of SRF (∼67 kDa), accompanied by the appearance of ∼20 kDa fragments. To validate the results, we used an antibody against the N-terminus of SRF (Novus Biologicals). As shown in Figure 2A bottom panel, an extra band at the molecular weight of ∼50 kDa was detected in addition to the full-length SRF following CVB3 infection of mouse cardiomyocytes at 20 h and 24 h. These data suggest that SRF is potentially cleaved during CVB3 infection to generate two cleavage products of approximately 50 and 20 kDa, respectively. We further examined the distribution of SRF following CVB3 infection of mouse cardiomyocytes using anti-C-terminal SRF antibody. Figure 2B showed that SRF was redistributed from the nucleus to the cytoplasm in CVB3-infected cells, whereas it remained in the nucleus of sham-infected cells.
Real-time RT-PCR was also carried out to examine the gene expression of SRF after CVB3 infection of mouse cardiomyocytes. The results in Figure 2C demonstrate unchanged mRNA levels of SRF following CVB3 infection, suggesting that the reduced protein expression of full-length SRF is unlikely due to decreased gene expression, but rather protein cleavage.
Cleavage of SRF following CVB3 infection
To further confirm cleavage of SRF, we utilized a HeLa cell line, a well-characterized model in CVB3 investigations amenable for transfection with plasmids. HeLa cells which express low levels of endogenous SRF were transiently transfected with a 3×FLAG-tagged SRF construct for 48 h followed by CVB3 infection for 7 h. Western blot was performed using anti-FLAG antibody or anti-C-terminal SRF antibody, which showed two cleavage products with molecular weights of ∼50 and ∼20 kDa, respectively (Figure 3). These results correspond well with our observation on endogenous SRF cleavage shown in Figure 2A.
Caspase-mediated SRF cleavage, which yields a 32-kDa protein fragment, has been reported in both non-cardiac and cardiac cells 19, 25, 26. To determine whether caspases are involved in CVB3-induced cleavage of SRF, we treated cells with z-VAD-fmk, a general caspase inhibitor. As shown in Figure 4, following CVB3 infection of SRF-transfected cells (lane 6), two cleavage products (∼50 and ∼40 kDa using anti-N-terminal FLAG antibody and of ∼30 and ∼20 kDa using anti-C-terminal SRF antibody) were detected. With addition of z-VAD-fmk (lane 7), the levels of the ∼40 kDa (upper panel) and the ∼30 kDa (middle panel) fragments were markedly reduced, indicating that they are the cleavage products of SRF by caspases. The appearances of the ∼40 kDa (upper panel) and the ∼30 kDa (middle panel) bands in SRF-transfected and sham-infected cells (lane 5) are likely due to transfection-induced cytotoxicity. It was noted that inhibition of caspase activation did not prevent the production of the ∼50 kDa (lane 7, upper panel) and the ∼20 kDa (lane 7, middle panel) fragments, suggesting that these cleavages are independent of caspase activation. Taken together, our results suggest that SRF is cleaved during CVB3 infection by viral protein and caspases at two different sites. Since caspase activation is a late event during viral infection, downregulation of cardiac genes in CVB3-infected mouse heart and cardiomyocytes may be mainly attributable to viral protease-mediated SRF cleavage.
Identification of SRF cleavage site during CVB3 infection
As illustrated in Figure 5A, SRF protein consists of two major domains: the SRE DNA binding and dimerization domain (amino acids 133 to 222) and the transactivation domain (amino acids 339 to 508). Computer prediction algorithm for cleavage sites by enteroviral proteases (NetPicoRNA V1.0 algorithm) revealed potential 2A protease site, which results in two products of ∼50 and ∼20 kDa (Figure 5A), consistent with the SRF fragments detected in CVB3-infected cells. First, we examined whether SRF can be cleaved by viral protease 2A. Figures 5B and 5C showed that overexpression of 2A resulted in two cleavage products of FLAG-tagged SRF with the molecular weights similar to those observed during CVB3 infection. This study suggests that CVB3 induces SRF cleavage through the action of viral protease 2A.
To confirm the cleavage site predicted by the computer algorithm, we constructed a SRF point mutant, in which the G residue at position 349 was replaced with E (G349E), by site-directed mutagenesis. However, we found that this mutant was still susceptible to cleavage during infection (Figure 6B, upper). To further identify the cleavage site of SRF, we constructed three deletion mutants and a series of point mutation plasmids (data not shown). We found that the G327E mutant was resistant to CVB3-induced cleavage (Figure 6B, lower), suggesting that SRF is cleaved after T326. Although this cleavage site is not predicted by the NetPicoRNA program, amino acid sequence alignments of SRF with other known 2A substrates at the cleavage region revealed a similar cleavage motif (Figure 6C).
Cellular localization and transcriptional function of CVB3-mediated SRF cleavage fragments
To understand the functional significance of CVB3-induced SRF cleavage, we generated two constructs expressing the N- and C-terminal SRF fragments, respectively. We showed that the SRF-N truncate harboring a DNA-binding domain and a nuclear localization signal was localized to the nucleus in both HeLa cells (Figure 7A) and HL-1 cardiomyocytes (Figure 7B) as expected, whereas SRF-C which carries a transcriptional activation domain was distributed in the cytoplasm (Figure 7A) or in both cytosol and nucleus (Figure 7B).
To determine the transcriptional activities of cleaved or non-cleavable SRFs, HeLa cells (Figure 7C) and HL-1 cardiomyocytes (Figure 7D) were transiently co-transfected with Firefly luciferase reporter construct containing cardiac α-actin promoter together with plasmids encoding full-length, truncated, or non-cleavable SRFs and LacZ (control). As displayed in Figure 7C and 7D, the cardiac α-actin promoter activities were strikingly increased with the addition of wild-type and non-cleavable forms of SRF. However, both SRF-N and SRF-C mutants lost their gene transcriptional functions. Our results suggest that CVB3-induced cleavage of SRF leads to the disruption of SRF-mediated gene transactivation.
In addition to loss of function of SRF, the presence of SRF cleavage products may themselves have detrimental effects on the function of native SRF. The N-terminal fragment of SRF contains an intact DNA-binding domain but lacks the C-terminal transactivation domain. To test whether this fragment can act as a dominant-negative competitor to full-length SRF, we co-transfected wild-type SRF together with SRF-N and SRF-C mutants in the presence of cardiac α-actin reporter and Renilla luciferase control plasmids into HeLa cells (Figure 7C) and HL-1 cardiomyocytes (Figure 7D). We demonstrated that the SRF-N mutant significantly decreased wild-type SRF-induced promoter activities of cardiac α-actin, suggesting a negative regulatory role of this mutant in regulating SRF function probably by competing for DNA binding.
Effects of CVB3-mediated SRF cleavage on viral replication
Viruses usually utilize or modulate the host cell infrastructure for their own replication. To test whether cleavage of SRF is beneficial to viral propagation within the host cells, finally, we examined the influences of SRF cleavage on viral replication. Figure 8 showed that neither knockdown of SRF nor overexpression of wild-type or truncated SRFs affects viral replication, suggesting that cleavage of SRF may not contribute directly to viral benefits.
Discussion
Enteroviral proteases have been recognized as an important contributor to viral pathogenesis and resultant myocardial dysfunction via the cleavage of important host proteins. Using a Cre/LoxP-inducible system, it has been shown that transgenic mice with cardiac-specific overexpression of protease 2A develop severe cardiac dysfunction and DCM 3. Experimental evidence from cell culture and cell-free in vitro studies demonstrates that viral protease 2A induces the cleavage and functional impairment of dystrophin 4. Dystrophin connects the cytoskeletal actin-binding site to the β-dystroglycan extracellular matrix anchor, thus its cleavage leads to the disruption of the cytoskeletal architecture. It is therefore proposed that protease 2A-induced DCM is associated with disrupted myocyte integrity via the cleavage of dystrophin 4. However, the mdx (dystrophin deficient) mice display a relatively mild dilated phenotype. This is attributed to the compensatory upregulation of the dystrophin homolog utrophin, as evidenced by severe dystrophic phenotype in mice with double knockout of utrophin and dystrophin 5, 6, 27, 28. Previous study has shown that CVB3 infection does not lead to cleavage of utrophin 4, thus the DCM phenotype induced by dystrophin cleavage may be dampened by the compensatory effect of utrophin in the CVB3-infected heart. All of these suggest that dystrophin cleavage alone may not be sufficient to explain the severe cardiomyopathy phenotype observed in 2A-transgenic mice. This prompts us to postulate that other substrate(s) of 2A may also play a role in the progression of virus-induced cardiomyopathy.
The major findings of this study are as follows: (1) cardiac-specific contractile and regulatory genes are downregulated in CVB3-infected mouse heart and cardiomyocytes, (2) SRF is cleaved by viral protease 2A during CVB3 infection, and (3) cleavage of SRF leads to the disruption of SRF-mediated gene transactivation and production of a dominant-negative competitor to native SRF. These findings suggest that SRF cleavage may contribute to cardiac dysfunction and subsequent progression to DCM in enteroviral myocarditis by disturbing the expression of cardiac contractile and regulatory genes.
Microarray studies in human end-stage heart failure revealed a significant downregulation of numerous cardiac genes, including genes with SRF-binding sites, implicating an important role of SRF in the progression of heart failure 22, 23, 24. In the present study, we provide the first evidence that cardiac-specific genes are also downregulated in enterovirus-infected heart and cultured cardiomyocytes. All these genes shown in Figure 1 have either been previously reported to be targets of SRF or contain SREs in their promoter regions 10, 29, 30.
It was reported that expression of an alternatively spliced SRF variant lacking portions of the transactivation domain is markedly increased in human and animal failing hearts 31, 32. This isoform functions as a dominant-negative mutant that inhibits SRF-dependent activation of cardiac muscle genes. Interestingly, our recent report showed that SRF cleavage also occurs in myocytes of severely failing human hearts. Increased caspase activity during heart failure induces the cleavage of SRF, producing a truncated protein that lacks the C-terminal transactivation domain, and acts as a dominant inhibitory transcription factor, similar to the alternatively spliced variant 19. These studies suggest that decreased production of full-length SRF, or increased accumulation of truncated SRF, may downregulate SRF-dependent genes and contribute to the progression of severe heart failure. In this study, we have identified a new cleavage site in SRF by viral protease 2A during virus infection and demonstrated a dominant-negative effect of the cleaved SRF on the expression of cardiac genes.
Coxsackievirus infection of heart results in focal lesions accompanied by severe fibrosis. Interestingly, recent research on mosaic regional inactivation of SRF in mouse hearts was found to be sufficient in inducing focal lesions and resulting in fatal DCM 33. In these mice, wild-type cardiomyocytes adjacent to the SRF-null myocytes undergo compensatory hypertrophy, which further triggers a hypertrophic response in remote wild-type cardiomyocytes to preserve cardiac output. This mosaic SRF inactivation model provides some insights into the possible pathophysiological consequences of non-functional SRF and dominant-negative SRF truncates presented in patches of CVB3-infected cardiomyocytes and their subsequent influences on the disease progression and outcome.
Overexpression of SRF has also been associated with cardiac hypertrophy. Transgenic mouse studies showed that the cardiac-specific overexpression of SRF induces a pattern of fetal gene re-expression similar to that observed in cardiac hypertrophy and subsequently causes a severe hypertrophic phenotype 34. Therefore, in the future, establishment of a knockin mouse model expressing non-cleavable SRF in the heart will be crucial to determine whether this form of SRF can rescue cardiomyocytes from CVB3-induced dysfunction.
In conclusion, our results provide new insights into the mechanisms by which virus infection impairs heart function and may further the development of new therapeutic approaches to ameliorating myocardial damage and progression to DCM.
Materials and Methods
Cell culture and in vitro CVB3 infection
The HL-1 cell line, a murine cardiac muscle cell line established from an AT-1 mouse atrial cardiomyocyte tumor lineage, was a generous gift from Dr William C Claycomb (Louisiana State University Medical Center, USA). Cells were plated and maintained in Claycomb medium (JRH Biosciences) supplemented with 10% fetal bovine serum, 100 μg/ml penicillin-streptomycin, 0.1 mM norepinephrine in ascorbic acid, and 2 mM L-glutamine as described previously 35. HL-1 cardiomyocytes were infected at a multiplicity of infection (MOI) of 10 with CVB3 (Kandolf strain) or sham infected with phosphate-buffered saline (PBS) for 1 h, washed with PBS, and placed in complete culture medium for various times.
HeLa cells were obtained from the American Type Culture Collection. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated newborn calf serum. HeLa cells were infected in a similar fashion as described above.
In vivo CVB3 infection and heart functional measurements
Male A/J mice at the age of ∼5 weeks were either infected intraperitoneally with 105 plaque-forming unit (p.f.u.) of CVB3 or sham infected with PBS for 3, 9, and 30 days. Heart function was measured before infection (day 0) and on days 3, 9, and 30 after CVB3 infection using two-dimensional echocardiography (Sonos 5500, Philips) with a 12 MHz S-12 probe (Sonos 5000). Parasternal long and short axis images at the level of the mitral valve and papillary muscles were taken and these measurements were normalized to changes in body weight and then utilized for calculation of functional parameters. All measurements were averaged for five consecutive cardiac cycles.
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Canadian Council on Animal Care. The protocol was approved by the Animal Care Committee of the University of British Columbia (#A03-0233).
Affymetrix array analysis
Hearts were harvested at 9 days following CVB3 infection and total RNA was isolated from mouse ventricular tissue using the RNeasy® isolation kit (Qiagen) and pooled (n = 4 for each group). Samples were hybridized to a custom mouse GeneChip® (Amgen) based on the Affymetrix GeneChip® Expression Analysis Technical Manual (Affymetrix). In vitro transcription was performed using an ENZO BioarrayTM HighYieldTM RNA Transcript Labeling kit as per the manufacturer's instructions. Arrays were washed in the Affymetrix Fluidics Station 450, stained with a streptavidin phycoerythrin solution and scanned using a HP Agilent GeneArray® Scanner.
Western blot analysis
Protein concentrations of cell or tissue lysates were determined by the Bradford assay (Bio-Rad Laboratories). Equal amounts of protein were subjected to SDS-PAGE and then transferred to a nitrocellulose membrane. The membrane was blocked with 5% non-fat dry milk solution containing 0.1% Tween-20 for 1 h. Afterwards, the membrane was probed for 1 h with the primary antibody, followed by incubation for 1 h with horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were visualized with enhanced chemiluminescence (SuperSignal).
The following antibodies were utilized: monoclonal anti-β-actin and anti-GAPDH (Sigma), monoclonal anti-VP1 (DakoCytomation), polyclonal anti-SRF N-terminus (Novus Biological), polyclonal anti-SRF C-terminus, anti-FLAG, and anti-eIF4γ (Santa Cruz Biotechnology).
Immunocytochemistry
Cells grown on glass slides were washed with PBS and fixed in 4% formaldehyde. Cells were then permeabilized with 0.1% Triton X-100 for 10 min, blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline (TBS) for 30 min. After incubation with primary antibodies at 4 °C overnight and then with anti-rabbit AlexaFluor 594 or anti-mouse AlexaFluor 488 IgG at room temperature for 1 h, cells were washed with PBS and then mounted on slides using VectaShield medium containing 4′,6-diamidino-2-phenylindole (DAPI). Cells were imaged and analyzed using a Leica SP2 AOBS confocal fluorescence microscope.
Real-time quantitative RT-PCR
Total RNAs were extracted from murine HL-1 cardiomyocytes at 24 h post infection. Following reverse transcription, the mRNA levels of SRF and cardiac genes were measured by real-time quantitative PCR using an ABI Prism 7900HT Sequence Detection System as per the manufacturers' instruction (Perkin-Elmer Applied Biosystems) as previously described 20 and normalized to GAPDH mRNA.
Constructs
The pCMV-3×FLAG-SRF construct, a generous gift from Dr Ron Prywes (Columbia University, USA), was used as the template for the generation of site-directed mutagenesis (SRFG349E and SRFG327E mutants). Truncated SRF cDNAs were generated by PCR using the following primers: SRF-N forward 5′-GTCGACTCTAGAATGTTACCG-3′ and reverse 5′-AGGAGACGGATCCGCTTCATG-3′; SRF-C forward 5′-CTGAAGTCTAGAGGCAGCGG-3′ and reverse 5′-ACCCGGGATCCTTTAGATCAT-3′. SRF-N and SRF-C cDNAs were subcloned into pCMV-3×FLAG vector using XbaI and BamHI restriction digestions.
Luciferase assay
HeLa and HL-1 cells at 90% confluence in 24-well tissue culture plates were transiently co-transfected with a Firefly luciferase reporter construct containing cardiac α-actin promoter 19 and a Renilla luciferease control vector (Promega) together with plasmids encoding full-length, truncated, or non-cleavable SRFs, and control LacZ. After 48 h, cell lysates were collected and analyzed for firefly and renilla luciferase activities using a dual luciferase reporter assay system (Promega) as per the manufacturer's instruction. The relative luciferase activities were normalized to the LacZ control group and presented as fold changes.
Plaque assay
Virus titer in cell supernatant was measured by an agar overlay plaque assay. In brief, cell supernatant was serially diluted and overlaid on a 90% to 95% confluent monolayer of HeLa cells. After 1 h of incubation, cells were washed with PBS and overlaid with complete DMEM containing 0.75% agar. At 3 days after infection, cells were fixed with Carnoy's fixative (75% ethanol and 25% acetic acid) and stained with 1% crystal violet. Plaques were counted, and the viral titer was determined as p.f.u./ml.
Small-interfering RNA (siRNA)
HeLa cells grown at 50% confluence were transfected with SRF or control siRNAs (Santa Cruz Biotechnology) using Lipofectamine 2000. After 48 h, cells were infected with CVB3 as described above. Cell supernatants and lysates were collected 7 h post infection and analyzed for viral titer and protein expression by plaque assay and western blotting, respectively.
Statistical analysis
Results are expressed as mean ± SD. Statistical analysis was performed with unpaired Student's t-test. P-values < 0.05 were considered to be statistically significant.
References
Luo H, Wong J, Wong B . Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy. Cardiovasc Res 2010; 85:347–356.
Yajima T, Knowlton KU . Viral myocarditis: from the perspective of the virus. Circulation 2009; 119:2615–2624.
Xiong D, Yajima T, Lim BK, et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 2007; 115:94–102.
Badorff C, Lee GH, Lamphear BJ, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5:320–326.
Deconinck AE, Rafael JA, Skinner JA, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997; 90:717–727.
Grady RM, Teng H, Nichol MC, et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997; 90:729–738.
Miano JM . Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol 2003; 35:577–593.
Niu Z, Li A, Zhang SX, Schwartz RJ . Serum response factor micromanaging cardiogenesis. Curr Opin Cell Biol 2007; 19:618–627.
Oka T, Xu J, Molkentin JD . Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol 2007; 18:117–131.
Sun Q, Chen G, Streb JW, et al. Defining the mammalian CArGome. Genome Res 2006; 16:197–207.
Liu N, Bezprozvannaya S, Williams AH, et al. MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008; 22:3242–3254.
Miano JM, Ramanan N . Georger MA, et al. Restricted inactivation of serum response factor to the cardiovascular system. Proc Natl Acad Sci USA 2004; 101:17132–17137.
Nelson TJ . Balza R Jr, Xiao Q, Misra RP . SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy. J Mol Cell Cardiol 2005; 39:479–489.
Niu Z, Iyer D . Conway SJ, et al. Serum response factor orchestrates nascent sarcomerogenesis and silences the biomineralization gene program in the heart. Proc Natl Acad Sci USA 2008; 105:17824–17829.
Small EM, O'Rourke JR, Moresi V, et al. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci USA 2010; 107:4218–4223.
Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129:303–317.
Parlakian A, Tuil D, Hamard G, et al. Targeted inactivation of serum response factor in the developing heart results in myocardial defects and embryonic lethality. Mol Cell Biol 2004; 24:5281–5289.
Parlakian A, Charvet C, Escoubet B, et al. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 2005; 112:2930–2939.
Chang J, Wei L, Otani T, et al. Inhibitory cardiac transcription factor, SRF-N, is generated by caspase 3 cleavage in human heart failure and attenuated by ventricular unloading. Circulation 2003; 108:407–413.
Cheung C, Marchant D, Walker EK, et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008; 117:1574–1582.
Marchant D, Dou Y, Luo H, et al. Bosentan enhances viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein kinase activation while improving cardiac function during coxsackievirus-induced myocarditis. Circ Res 2009; 104:813–821.
Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC . Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002; 160:2035–2043.
Hwang JJ, Allen PD, Tseng GC, et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 2002; 10:31–44.
Tan FL, Moravec CS . Li J, et al. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci USA 2002; 99:11387–11392.
Bertolotto C, Ricci JE . Luciano F, et al. Cleavage of the serum response factor during death receptor-induced apoptosis results in an inhibition of the c-FOS promoter transcriptional activity. J Biol Chem 2000; 275:12941–12947.
Drewett V, Devitt A . Saxton J, et al. Serum response factor cleavage by caspases 3 and 7 linked to apoptosis in human BJAB cells. J Biol Chem 2001; 276:33444–33451.
Hainsey TA, Senapati S, Kuhn DE, Rafael JA . Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscul Disord 2003; 13:294–302.
Janssen PM, Hiranandani N, Mays TA, Rafael-Fortney JA . Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 2005; 289:H2373–2378.
Balza RO Jr, Misra RP . Role of the serum response factor in regulating contractile apparatus gene expression and sarcomeric integrity in cardiomyocytes. J Biol Chem 2006; 281:6498–6510.
Chai J, Tarnawski AS . Serum response factor: discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharmacol 2002; 53:147–157.
Belaguli NS, Zhou W, Trinh TH, Majesky MW, Schwartz RJ . Dominant negative murine serum response factor: alternative splicing within the activation domain inhibits transactivation of serum response factor binding targets. Mol Cell Biol 1999; 19:4582–4591.
Davis FJ, Gupta M, Pogwizd SM, et al. Increased expression of alternatively spliced dominant-negative isoform of SRF in human failing hearts. Am J Physiol Heart Circ Physiol 2002; 282:H1521–H1533.
Gary-Bobo G, Parlakian A, Escoubet B, et al. Mosaic inactivation of the serum response factor gene in the myocardium induces focal lesions and heart failure. Eur J Heart Fail 2008; 10:635–645.
Zhang X, Azhar G, Chai J, et al. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am J Physiol Heart Circ Physiol 2001; 280:H1782–H1792.
Luo H, Zhang J, Cheung C, et al. Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am J Pathol 2003; 163:381–385.
Acknowledgements
This work was supported by the Heart and Stroke Foundation of British Columbia and Yukon (to HL), the Canadian Institutes of Health Research (to HL), the American Heart Association (0855030F to JC) and the American National Institutes of Health (R01HL102314, R21HL094844 and K0202HL098956 to JC). JW was awarded the Studentship from the Canadian Institutes of Health Research.
Author information
Authors and Affiliations
Corresponding author
Additional information
( Supplementary information is linked to the online version of the paper on the Cell Research website.)
Supplementary information
Supplemental information, Table S1
Affymetrix microarray analyses of CVB3-infected mouse heart. (XLS 83 kb)
Rights and permissions
About this article
Cite this article
Wong, J., Zhang, J., Yanagawa, B. et al. Cleavage of serum response factor mediated by enteroviral protease 2A contributes to impaired cardiac function. Cell Res 22, 360–371 (2012). https://doi.org/10.1038/cr.2011.114
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cr.2011.114
Keywords
This article is cited by
-
SRF: a seriously responsible factor in cardiac development and disease
Journal of Biomedical Science (2022)
-
SG formation relies on eIF4GI-G3BP interaction which is targeted by picornavirus stress antagonists
Cell Discovery (2019)
-
Approaches to identify and characterize microProteins and their potential uses in biotechnology
Cellular and Molecular Life Sciences (2018)
-
Cleavage of DAP5 by coxsackievirus B3 2A protease facilitates viral replication and enhances apoptosis by altering translation of IRES-containing genes
Cell Death & Differentiation (2016)
-
Serum Response Factor Protects Retinal Ganglion Cells Against High-Glucose Damage
Journal of Molecular Neuroscience (2016)